Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
KannaSwiss is a Swiss-based biotechnology and healthcare company specializing in the production and distribution of high-quality legal cannabis and CBD products. Founded in 2014, the company operates a large-scale, GMP-certified facility in Switzerland, focusing on the extraction of cannabinoids like CBD and CBG for medical and wellness applications. Their product portfolio includes bulk isolates, distillates, and finished consumer goods such as oils and topicals. KannaSwiss emphasizes science-led formulation and rigorous quality control to serve the global pharmaceutical and nutraceutical markets. In 2021, the company was acquired by The House of Agriculture (THC) to expand its international footprint and production capabilities.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on KannaSwiss.